Related Experiment Videos
Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination
D Yeshurun1, R Abukarshin, N Elias
1Department of Medicine A, B'nai Zion Medical Center, Technion, Haifa, Israel.
Insights
Combined bezafibrate-lovastatin therapy effectively lowers cholesterol and triglycerides in patients with severe familial combined hyperlipidemia (FCHL). This combination treatment showed good tolerance, offering a potential option for resistant cases.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Metabolic Disorders
Background:
- Familial combined hyperlipidemia (FCHL) is a prevalent genetic lipid disorder characterized by elevated cholesterol and triglyceride levels.
- The primary metabolic defect in FCHL involves the overproduction of apolipoprotein B-100.
- FCHL is associated with high atherogenicity, increasing the risk of cardiovascular disease.
Purpose of the Study:
- To evaluate the efficacy and tolerability of combined bezafibrate-lovastatin therapy in patients with severe, treatment-resistant FCHL.
- To assess the impact of combination therapy on lipid profiles, including total cholesterol, LDL cholesterol, and triglycerides.
Main Methods:
- A cohort of 10 patients with FCHL and high lipid levels, unresponsive to diet and bezafibrate alone, was treated.
- Patients received bezafibrate (600 mg/day) combined with lovastatin (20 mg/day for 6 weeks, then 40 mg/day for 6 weeks).
- Lipid levels and potential side effects were monitored throughout the treatment period.
Main Results:
- The addition of lovastatin 20 mg/day led to significant reductions: 15% in total cholesterol, 20% in LDL cholesterol, and 13% in triglycerides.
- Increasing lovastatin to 40 mg/day resulted in further moderate decreases of 4%, 3%, and 8% in total cholesterol, LDL cholesterol, and triglycerides, respectively.
- The combination therapy was well-tolerated, with no significant adverse events or laboratory abnormalities reported by patients.
Conclusions:
- Combined bezafibrate-lovastatin therapy is a viable therapeutic option for managing severe and resistant cases of familial combined hyperlipidemia.
- Despite concerns about combining fibrates and statins, this regimen demonstrated good tolerability in the studied patient group.
- Close medical supervision is recommended due to the potential for side effects associated with combination lipid-lowering therapy.
Abstract:
Familial combined hyperlipidemia (FCHL) is a common lipid disorder characterized by high levels of cholesterol, triglycerides, or both. The basic metabolic abnormality is overproduction of apolipoprotein B-100. High atherogenicity has been attributed to all forms of FCHL. We evaluated combined bezafibrate-lovastatin therapy in 10 patients (9 men and 1 woman) with FCHL and markedly high cholesterol and triglyceride levels who were at high risk of coronary artery disease and who had not responded to diet and bezafibrate treatment alone. Eight patients had coronary artery disease, 6 had hypertension, and 3 had noninsulin-dependent diabetes mellitus. Lovastatin 20 mg/day was added to the bezafibrate 600 mg/day regimen for 6 weeks; the lovastatin dosage was then doubled to 40 mg/day for an additional 6 weeks. The addition of 20 mg of lovastatin resulted in decreases of 15%, 20%, and 13% in total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride levels, respectively. Increasing the dose of lovastatin to 40 mg resulted in further moderate decreases of 4%, 3%, and 8% in total cholesterol, LDL cholesterol, and triglycerides, respectively, compared with the 20 mg/day dosage. Although previous reports have emphasized the potential side effects of combination treatment with lovastatin and fibric acid derivatives, our patients tolerated the regimen well, with no significant subjective complaints or laboratory abnormalities. The bezafibrate-lovastatin combination is a possible therapeutic option for severe, resistant FCHL, but close medical supervision is needed because of potential side effects.